曲伐沙星（CP-99,219）对从腹腔内感染患者分离出的221株需氧菌和217株厌氧菌的体外比较活性。
Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
作者信息
Citron D M, Appleman M D
机构信息
Microbial Research Laboratory, LAC+USC Medical Center, Los Angeles, California 90033, USA.
出版信息
Antimicrob Agents Chemother. 1997 Oct;41(10):2312-6. doi: 10.1128/AAC.41.10.2312.
Abstract
Four hundred thirty-eight bacteria cultured from specimens of patients with serious intra-abdominal infections were tested by agar dilution against trovafloxacin and other quinolones and antimicrobial agents. Trovafloxacin inhibited 435 strains (99.3%) at < or =2 microg/ml. All the quinolones had similar activities against Enterobacteriaceae and Pseudomonas sp., but trovafloxacin showed superior activities against streptococci, enterococci, and anaerobic organisms. Because of its excellent in vitro activities against diverse bacteria, trovafloxacin has potential use as a single agent for polymicrobial infections.
摘要
对从严重腹腔内感染患者标本中培养出的438株细菌，采用琼脂稀释法针对曲伐沙星、其他喹诺酮类药物及抗菌剂进行了测试。曲伐沙星在浓度≤2微克/毫升时可抑制435株菌株（99.3%）。所有喹诺酮类药物对肠杆菌科细菌和假单胞菌属的活性相似，但曲伐沙星对链球菌、肠球菌及厌氧菌显示出更强的活性。由于其对多种细菌具有出色的体外活性，曲伐沙星有潜力作为单一药物用于混合感染。
相似文献
1
Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.曲伐沙星（CP-99,219）对从腹腔内感染患者分离出的221株需氧菌和217株厌氧菌的体外比较活性。
Antimicrob Agents Chemother. 1997 Oct;41(10):2312-6. doi: 10.1128/AAC.41.10.2312.
2
Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.曲伐沙星、环丙沙星、氧氟沙星及广谱β-内酰胺类药物对需氧血培养分离菌株的体外活性比较
Zentralbl Bakteriol. 1998 Dec;288(4):509-18. doi: 10.1016/s0934-8840(98)80070-4.
3
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.曲伐沙星对557株厌氧菌的体外活性
Antimicrob Agents Chemother. 1996 Sep;40(9):2232-5. doi: 10.1128/AAC.40.9.2232.
4
In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.莫西沙星对900株来自腹腔内感染和糖尿病足感染患者的需氧及厌氧手术分离菌株的体外活性。
Antimicrob Agents Chemother. 2004 Mar;48(3):1012-6. doi: 10.1128/AAC.48.3.1012-1016.2004.
5
Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.曲伐沙星（CP 99,219）与其他抗菌药物对临床重要厌氧菌的体外活性比较
Antimicrob Agents Chemother. 1997 Feb;41(2):484-7. doi: 10.1128/AAC.41.2.484.
6
Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.曲伐沙星（CP-99,219）对445株来自心内膜炎患者和其他血流感染患者的革兰氏阳性分离株的体外活性比较
Antimicrob Agents Chemother. 1997 May;41(5):1146-9. doi: 10.1128/AAC.41.5.1146.
7
The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.新型氟喹诺酮类药物托氟沙星与环丙沙星和替马沙星的体外活性比较。
J Antimicrob Chemother. 1991 Nov;28(5):719-25. doi: 10.1093/jac/28.5.719.
8
In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.克林沙星（CI-960）和PD 131628-2对厌氧菌的体外活性
J Antimicrob Chemother. 1994 Oct;34(4):579-84. doi: 10.1093/jac/34.4.579.
9
The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.曲伐沙星及其他九种抗菌药物对413株厌氧菌的体外活性
J Antimicrob Chemother. 1996 Aug;38(2):271-81. doi: 10.1093/jac/38.2.271.
10
Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.新型喹诺酮类药物加替沙星对从普通外科、血管外科、心胸外科和耳鼻喉科手术患者中分离出的需氧和厌氧微生物菌株的体外抗菌活性比较
J Antimicrob Chemother. 2005 Nov;56(5):872-8. doi: 10.1093/jac/dki348. Epub 2005 Sep 26.
引用本文的文献
1
The new fluoroquinolones: A critical review.新型氟喹诺酮类药物：批判性综述。
Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.
2
In vitro activities of a new des-fluoroquinolone, BMS 284756, and seven other antimicrobial agents against 151 isolates of Eikenella corrodens.新型去氟喹诺酮类药物BMS 284756与其他七种抗菌药物对151株腐蚀艾肯菌的体外活性
Antimicrob Agents Chemother. 2002 Apr;46(4):1141-3. doi: 10.1128/AAC.46.4.1141-1143.2002.
3
Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.在体外药效学模型中曲伐沙星和左氧氟沙星对脆弱拟杆菌的药效学研究
Antimicrob Agents Chemother. 2002 Jan;46(1):203-10. doi: 10.1128/AAC.46.1.203-210.2002.
4
Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.在体外药效学模型中，厌氧细菌暴露于左氧氟沙星、曲伐沙星和司帕沙星后对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 2001 Jul;45(7):2136-40. doi: 10.1128/AAC.45.7.2136-2140.2001.
5
In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.采用厌氧时间杀菌技术测定曲伐沙星在与大肠杆菌或耐万古霉素屎肠球菌混合培养时对脆弱拟杆菌的体外活性。
Antimicrob Agents Chemother. 2001 Jan;45(1):243-51. doi: 10.1128/AAC.45.1.243-251.2001.
6
Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.gyrA基因突变在脆弱拟杆菌临床分离株及体外突变株对新型氟喹诺酮类药物曲伐沙星耐药性中的作用。
Antimicrob Agents Chemother. 2000 Jul;44(7):1842-5. doi: 10.1128/AAC.44.7.1842-1845.2000.
7
Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.单剂量静脉注射阿拉曲沙星后，氟萘啶酮（曲伐沙星，CP 99,219）在婴幼儿和儿童中的药代动力学。
Antimicrob Agents Chemother. 2000 May;44(5):1195-9. doi: 10.1128/AAC.44.5.1195-1199.2000.
8
Fluoroquinolone treatment of skin and skin structure infections.
Drugs. 1999;58 Suppl 2:82-4. doi: 10.2165/00003495-199958002-00016.
9
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.司帕沙星暴露后脆弱拟杆菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251.
10
Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.新型喹诺酮类药物在腹腔内感染治疗中的应用：聚焦于克林沙星
Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522.
本文引用的文献
1
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.曲伐沙星对557株厌氧菌的体外活性
Antimicrob Agents Chemother. 1996 Sep;40(9):2232-5. doi: 10.1128/AAC.40.9.2232.
2
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.曲伐沙星（CP-99,219）的体内疗效，一种对革兰氏阳性病原体、肺炎链球菌和脆弱拟杆菌具有广泛活性的新型喹诺酮类药物。
Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6. doi: 10.1128/AAC.39.10.2210.
3
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.新型氟喹诺酮类药物CP-99,219对革兰氏阳性菌临床分离株的体外活性
Antimicrob Agents Chemother. 1993 Feb;37(2):366-70. doi: 10.1128/AAC.37.2.366.
4
In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.新型氟环丙基喹诺酮DU-6859a的体外活性
Antimicrob Agents Chemother. 1993 Dec;37(12):2747-53. doi: 10.1128/AAC.37.12.2747.
5
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.新型氮杂双环萘啶酮CP-99,219的体外抗菌活性
Antimicrob Agents Chemother. 1993 Feb;37(2):349-53. doi: 10.1128/AAC.37.2.349.
6
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.CP 99,219与环丙沙星、格帕沙星、甲硝唑、头孢西丁、哌拉西林及哌拉西林-他唑巴坦对489株厌氧菌的抗菌活性比较
Antimicrob Agents Chemother. 1994 Oct;38(10):2471-6. doi: 10.1128/AAC.38.10.2471.
7
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.环丙沙星、氧氟沙星、司帕沙星、替马沙星、CI-960、CI-990和WIN 57273对厌氧菌的比较活性。
Antimicrob Agents Chemother. 1992 May;36(5):1158-62. doi: 10.1128/AAC.36.5.1158.
Zotero 插件